[go: up one dir, main page]

DK2906252T3 - Pyrrolobenzodiazepin-Anti-Her2-antistofkonjugater - Google Patents

Pyrrolobenzodiazepin-Anti-Her2-antistofkonjugater Download PDF

Info

Publication number
DK2906252T3
DK2906252T3 DK13788691.7T DK13788691T DK2906252T3 DK 2906252 T3 DK2906252 T3 DK 2906252T3 DK 13788691 T DK13788691 T DK 13788691T DK 2906252 T3 DK2906252 T3 DK 2906252T3
Authority
DK
Denmark
Prior art keywords
antibody
mmol
cancer
conjugate
methoxy
Prior art date
Application number
DK13788691.7T
Other languages
English (en)
Inventor
Philip Wilson Howard
Berkel Patricius Hendrikus Cornelis Van
Original Assignee
Adc Therapeutics Sa
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adc Therapeutics Sa, Medimmune Ltd filed Critical Adc Therapeutics Sa
Application granted granted Critical
Publication of DK2906252T3 publication Critical patent/DK2906252T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (14)

1. Konjugat med formlen ConjA:
hvor Ab er et antistof, der binder til HER2, hvor antistoffet omfatter et VH-domæne med sekvensen ifølge SEQ ID NO. 1; og hvor lægemiddelladningen (p) af lægemidler (D) til antistof (Ab) er et heltal fra 1 til ca. 8.
2. Konjugat ifølge krav 1, hvor antistoffet omfatter et VH-domæne parret med et VL-domæne, hvor VH- og VL-domænerne har sekvenser med SEQ ID NO. 1 parret med SEQ ID NO. 2.
3. Konjugat ifølge enten krav 1 eller krav 2, hvor antistoffet er et intakt antistof.
4. Konjugat ifølge krav 3, hvor antistoffet omfatter en tung kæde med sekvensen ifølge SEQ ID NO. 3 parret med en let kæde med sekvensen ifølge SEQ ID NO.4.
5. Konjugat ifølge krav 4, hvor antistoffet omfatter to tunge kæder med sekvensen ifølge SEQ ID NO. 3, hver især parret med en let kæde med sekvensen ifølge SEQ ID NO. 4.
6. Konjugat ifølge et af kravene 1 til 5, hvor antistoffet er humaniseret, deim-muniseret eller overfladeomdannet.
7. Konjugat ifølge krav 1, hvor p er 1,2, 3 eller 4.
8. Konjugat ifølge krav 1, omfattende en blanding af antistof-lægemiddel-konjugatforbindelserne, hvor den gennemsnitlige lægemiddel-ladning pr. antistof i blandingen af antistof-lægemiddelkonjugatforbindelser er ca. 2 til ca. 5.
9. Konjugat ifølge et af kravene 1 til 8 til anvendelse i terapi.
10. Konjugat ifølge et af kravene 1 til 8 til anvendelse ved behandling af en proliferativ sygdom hos et individ.
11. Konjugat ifølge krav 10, hvor sygdommen er cancer.
12. Konjugat ifølge krav 11, hvor canceren er udvalgt fra gruppen bestående af: brystkræft, mavekræft, blærekræft, pancreaskræft, kolorektal kræft, livmoderhalskræft, æggestokkræft, prostatakræft, ikke-småcellet lungekræft, endometriekræft, hoved- og halskræft og spytkirtelkarcinom.
13. Farmaceutisk sammensætning omfattende konjugatet ifølge et af kravene 1 til 8 og et farmaceutisk acceptabelt fortyndingsmiddel, bærer eller exci-piens.
14. Farmaceutisk sammensætning ifølge krav 13, endvidere omfattende en terapeutisk virksom mængde af et kemoterapeutisk middel.
DK13788691.7T 2012-10-12 2013-10-11 Pyrrolobenzodiazepin-Anti-Her2-antistofkonjugater DK2906252T3 (da)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201261712924P 2012-10-12 2012-10-12
US201261712928P 2012-10-12 2012-10-12
US201361784270P 2013-03-14 2013-03-14
US201361784233P 2013-03-14 2013-03-14
US201361784249P 2013-03-14 2013-03-14
PCT/EP2013/071343 WO2014057115A1 (en) 2012-10-12 2013-10-11 Pyrrolobenzodiazepine-anti-her2 antibody conjugates

Publications (1)

Publication Number Publication Date
DK2906252T3 true DK2906252T3 (da) 2017-09-11

Family

ID=49552324

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13788691.7T DK2906252T3 (da) 2012-10-12 2013-10-11 Pyrrolobenzodiazepin-Anti-Her2-antistofkonjugater

Country Status (22)

Country Link
US (1) US20150273077A1 (da)
EP (1) EP2906252B1 (da)
JP (1) JP2016502504A (da)
KR (1) KR20150083856A (da)
CN (1) CN104955485B (da)
AU (1) AU2013328621B2 (da)
BR (1) BR112015008177A2 (da)
CA (1) CA2887896A1 (da)
CY (1) CY1119287T1 (da)
DK (1) DK2906252T3 (da)
ES (1) ES2640449T3 (da)
HR (1) HRP20171264T1 (da)
HU (1) HUE034505T2 (da)
LT (1) LT2906252T (da)
MX (1) MX2015004423A (da)
PL (1) PL2906252T3 (da)
PT (1) PT2906252T (da)
RS (1) RS56222B1 (da)
SI (1) SI2906252T1 (da)
SM (1) SMT201700444T1 (da)
WO (1) WO2014057115A1 (da)
ZA (1) ZA201502267B (da)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0819095D0 (en) 2008-10-17 2008-11-26 Spirogen Ltd Pyrrolobenzodiazepines
EP2789622B1 (en) 2010-04-15 2017-03-01 MedImmune Limited Pyrrolobenzodiazepines used to treat proliferative diseases
KR101772354B1 (ko) 2010-04-15 2017-08-28 시애틀 지네틱스, 인크. 표적화된 피롤로벤조디아제핀 접합체
JP6170494B2 (ja) 2011-09-20 2017-07-26 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン
ES2687246T3 (es) 2011-10-14 2018-10-24 Seattle Genetics, Inc. Pirrolobenzodiazepinas y conjugados dirigidos
EP3309162A1 (en) 2011-10-14 2018-04-18 Seattle Genetics, Inc. Targeted conjugates of pyrrolobenzodiazepines
AU2012322932B2 (en) 2011-10-14 2016-11-10 Medimmune Limited Pyrrolobenzodiazepines
KR101891859B1 (ko) 2011-10-14 2018-08-24 메디뮨 리미티드 피롤로벤조디아제핀
MX338711B (es) 2012-10-12 2016-04-28 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de las mismas.
AU2013328673B2 (en) 2012-10-12 2017-07-13 Medimmune Limited Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation
US9415117B2 (en) 2012-10-12 2016-08-16 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
CA2894959C (en) 2012-12-21 2022-01-11 Spirogen Sarl Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
EA031585B1 (ru) 2012-12-21 2019-01-31 Медимьюн Лимитед Пирролобензодиазепины и их конъюгаты
US9821074B2 (en) 2013-03-13 2017-11-21 Genentech, Inc. Pyrrolobenzodiazepines and conjugates thereof
NZ710746A (en) 2013-03-13 2018-11-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
WO2015052534A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
GB201317981D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
CN106687141A (zh) * 2014-09-10 2017-05-17 麦迪穆有限责任公司 吡咯并苯并二氮杂卓及其缀合物
US9518118B2 (en) 2014-09-12 2016-12-13 Genentech, Inc. Anti-HER2 antibodies and immunoconjugates
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
MX2017003472A (es) * 2014-09-17 2017-10-31 Genentech Inc Inmunoconjugados que comprenden anticuerpos anti-her2.
WO2016083468A1 (en) 2014-11-25 2016-06-02 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
US9504694B2 (en) 2015-03-19 2016-11-29 Cellerant Therapeutics, Inc. Isoquinolidinobenzodiazepines
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201506389D0 (en) * 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506394D0 (en) * 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
US10689458B2 (en) 2015-11-30 2020-06-23 Pfizer Inc. Site specific HER2 antibody drug conjugates
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
CN106248971B (zh) * 2016-08-19 2017-10-03 合肥瀚科迈博生物技术有限公司 用于检测人血清中her2含量的elisa试剂盒、使用方法及用途
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
GB201619490D0 (en) * 2016-11-17 2017-01-04 Medimmune Ltd Pyrrolobenzodiazepine conjugates
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
ES2871001T3 (es) * 2017-02-08 2021-10-28 Adc Therapeutics Sa Conjugados de pirrolobenzodiazepinas y anticuerpos
BR112019016420A2 (pt) 2017-02-08 2020-04-07 Adc Therapeutics Sa conjugados pirrolobenzodiazepina-anticorpo
RS63502B1 (sr) 2017-04-18 2022-09-30 Medimmune Ltd Konjugati pirolobenzodiazepina
EP3612234B1 (en) 2017-04-20 2024-03-13 ADC Therapeutics SA Combination therapy with an anti-axl antibody-drug conjugate
WO2018193104A1 (en) 2017-04-20 2018-10-25 Adc Therapeutics Sa Combination therapy with an anti-cd25 antibody-drug conjugate
US11426467B2 (en) 2017-06-14 2022-08-30 Adc Therapeutics Sa Dosage regimes for the administration of an anti-CD25 ADC
BR112020003003A2 (pt) 2017-08-18 2020-08-11 Medimmune Limited conjugados de pirrolobenzodiazepina
CN116999572A (zh) 2017-09-29 2023-11-07 第一三共株式会社 抗体－药物偶联物、药物组合物及其在制备治疗肿瘤的药物中的应用
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
JP7177848B2 (ja) 2018-03-28 2022-11-24 田辺三菱製薬株式会社 ｃＭＥＴモノクローナル結合剤の薬物複合体とその使用
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
US11141490B2 (en) * 2018-07-13 2021-10-12 Research Foundation Of The City University Of New York Antibody-drug conjugates based on gold compounds
KR20210139270A (ko) 2019-03-15 2021-11-22 메드임뮨 리미티드 암의 치료에 사용하기 위한 아제티도벤조디아제핀 이량체 및 이를 포함하는 컨쥬게이트
EP3949987A4 (en) * 2019-03-25 2023-02-22 Daiichi Sankyo Company, Limited Anti-her2 antibody-pyrrolobenzodiazepine derivative conjugate
GB201908128D0 (en) * 2019-06-07 2019-07-24 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
CA3148611A1 (en) 2019-08-12 2021-02-18 Regeneron Pharmaceuticals, Inc. Macrophage stimulating 1 receptor (mst1r) variants and uses thereof
GB202011993D0 (en) 2020-07-31 2020-09-16 Adc Therapeutics Sa ANTI-IL 13Ra2 antibodies
WO2024005123A1 (ja) 2022-06-30 2024-01-04 東レ株式会社 癌の治療及び／又は予防用医薬組成物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2270010T3 (da) * 2004-03-01 2012-05-14 Spirogen Ltd 11-hydroxy-5h-pyrrolo[2,1-c][1,4]benzodiazepin-5-on-derivater som vigtige mellemprodukter i fremstillingen af c2-substituerede pyrrolobenzodiazepiner
GB0508084D0 (en) * 2005-04-21 2005-06-01 Spirogen Ltd Pyrrolobenzodiazepines
US20080112961A1 (en) * 2006-10-09 2008-05-15 Macrogenics, Inc. Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same
GB0819095D0 (en) * 2008-10-17 2008-11-26 Spirogen Ltd Pyrrolobenzodiazepines
CA2765418A1 (en) * 2009-06-26 2010-12-29 Five Prime Therapeutics, Inc. Therapeutic antibody target validation and screening in vivo
KR101772354B1 (ko) * 2010-04-15 2017-08-28 시애틀 지네틱스, 인크. 표적화된 피롤로벤조디아제핀 접합체
PH12012501836A1 (en) * 2010-04-15 2013-02-04 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
EP2789622B1 (en) * 2010-04-15 2017-03-01 MedImmune Limited Pyrrolobenzodiazepines used to treat proliferative diseases
US9586996B2 (en) * 2010-04-30 2017-03-07 Esperance Pharmaceuticals, Inc. Lytic-peptide-Her2/neu (human epidermal growth factor receptor 2) ligand conjugates and methods of use
PT2707031T (pt) * 2011-05-08 2019-09-05 Legochem Biosciences Inc Conjugados de proteína e agente ativo e processo para a sua preparação
KR101877598B1 (ko) * 2011-10-14 2018-07-11 메디뮨 리미티드 피롤로벤조디아제핀 및 그의 컨주게이트
WO2013177481A1 (en) * 2012-05-25 2013-11-28 Immunogen, Inc. Benzodiazepines and conjugates thereof

Also Published As

Publication number Publication date
HRP20171264T1 (hr) 2017-10-20
RS56222B1 (sr) 2017-11-30
JP2016502504A (ja) 2016-01-28
CA2887896A1 (en) 2014-04-17
EP2906252B1 (en) 2017-06-14
SMT201700444T1 (it) 2017-11-15
AU2013328621A1 (en) 2015-04-23
WO2014057115A1 (en) 2014-04-17
CY1119287T1 (el) 2018-02-14
AU2013328621B2 (en) 2016-12-01
MX2015004423A (es) 2015-10-29
ES2640449T3 (es) 2017-11-03
PL2906252T3 (pl) 2017-11-30
ZA201502267B (en) 2017-09-27
HUE034505T2 (en) 2018-02-28
BR112015008177A2 (pt) 2017-09-19
SI2906252T1 (sl) 2017-10-30
CN104955485A (zh) 2015-09-30
LT2906252T (lt) 2017-09-11
PT2906252T (pt) 2017-09-19
CN104955485B (zh) 2018-01-30
KR20150083856A (ko) 2015-07-20
US20150273077A1 (en) 2015-10-01
EP2906252A1 (en) 2015-08-19

Similar Documents

Publication Publication Date Title
DK2906252T3 (da) Pyrrolobenzodiazepin-Anti-Her2-antistofkonjugater
DK2906253T3 (da) Pyrrolobenzodiazepin-anti-psma-antistofkonjugater
DK2906298T3 (da) Pyrrolobenzodiazepin-antistofkonjugater
DK2906296T3 (da) Pyrrolobenzodiazepin-antistof-konjugater
EP2906250B1 (en) Pyrrolobenzodiazepine-anti-psma antibody conjugates
EP2906251B1 (en) Pyrrolobenzodiazepine-anti-cd22 antibody conjugates
EP2906297B1 (en) Pyrrolobenzodiazepine-antibody conjugates
US9956299B2 (en) Pyrrolobenzodiazepine—antibody conjugates
US9950078B2 (en) Pyrrolobenzodiazepine-antibody conjugates
US10010624B2 (en) Pyrrolobenzodiazepine-antibody conjugates
CA2885315C (en) Pyrrolobenzodiazepines and conjugates thereof
US20160256561A1 (en) Pyrrolobenzodiazepine-antibody conjugates
AU2014333762A1 (en) Pyrrolobenzodiazepines and conjugates thereof